Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | RIOK2 | Q9BVS4 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | VNN1 | O95497 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4310873 | 0.88 | ALOX5 (0.56) | CYP1A2CYP2A6ALOX5L3MBTL1MEN1 | |
| SCHEMBL21705053 | 0.83 | NR1H4 (0.58) | CYP1A2CYP2A6SMN1; SMN2ALOX5L3MBTL1 | |
| SCHEMBL6341622 | 0.83 | ALOX5 (0.51) | CYP1A2CYP2A6ALOX5L3MBTL1MEN1 | |
| SCHEMBL11634753 | 0.82 | ALOX5 (0.50) | CYP1A2CYP2A6ALOX5L3MBTL1MEN1 | |
| SCHEMBL23662913 | 0.82 | IAPP (0.60) | CYP1A2CYP2A6NPC1ALDH1A1RAB9A | |
| SCHEMBL3828870 | 0.82 | CYP1A2 (0.49) | CYP1A2CYP2A6NPC1ALDH1A1RAB9A | |
| SCHEMBL8077463 | 0.81 | ALOX5 (0.50) | CYP1A2CYP2A6ALOX5L3MBTL1RIOK2 | |
| SCHEMBL265881 | 0.81 | L3MBTL1 (0.56) | CYP1A2CYP2A6ALDH1A1SMN1; SMN2ALOX5 | |
| SCHEMBL13653061 | 0.81 | AKR1C3 (0.71) | CYP1A2NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5953968 | 0.81 | SIGMAR1 (0.50) | CYP1A2CYP2A6ALOX5L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024497-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-9890123-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | disclosed |
| WO-2016010950-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | CYP1A2 882/4885CYP2A6 1890/4885NPC1 3684/4885 |
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | CYP1A2 740/4885CYP2A6 242/4885NPC1 2957/4885 |
| US-20240024497-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | RNGTT, RNMT, DNPEP | CYP1A2 1589/4885CYP2A6 899/4885NPC1 1375/4885 |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | CYP1A2 2291/4885CYP2A6 1635/4885NPC1 1331/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | CYP1A2 2291/4885CYP2A6 1635/4885NPC1 1331/4885 |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | YEATS2, YEATS4, KNTC1 | CYP1A2 4168/4885CYP2A6 4559/4885NPC1 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.